KIA
VYGR icon

Kraematon Investment Advisors’s Voyager Therapeutics VYGR Stock Holding History

Kraematon Investment Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$6.1K – 250
2022
Q4 		$6.1K Buy
+1,000
New +$5.68K 0.01% 217

Other funds holding VYGR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Kraematon Investment Advisors's VYGR Position: Q1 2023 in Review

Kraematon Investment Advisors sold out of Voyager Therapeutics (VYGR) in Q1 2023, closing a stake of 1,000 shares — an estimated $6.1K sold.

Kraematon Investment Advisors first reported a position in VYGR in Q4 2022 and held it in 1 quarter. The position peaked at $6.1K in Q4 2022. 81 funds tracked by Wall St. Rank hold VYGR as of Q1 2023.

  • Kraematon Investment Advisors reported no remaining Voyager Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Kraematon Investment Advisors sold 1,000 Voyager Therapeutics shares in Q1 2023, an estimated $6.1K.
  • Kraematon Investment Advisors first reported a position in Voyager Therapeutics in Q4 2022 and held it in 1 quarter.
  • Kraematon Investment Advisors's Voyager Therapeutics position peaked at $6.1K in Q4 2022.
  • 81 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2023.

Based on Kraematon Investment Advisors's 13F filing for Q1 2023, filed 13 Apr 2023.